Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Effect of Anti-Inflammatory Inflixmab on General Cognition in Individuals with Bipolar I/II Depression
EF 2016-17
Résumé
Bipolar Depression (BD) is a significant contributor to global disability worldwide. Functional impairments such as deficits in cognitive performance after a depressive episode costs the Canadian economy over $6.3 billion annually. Increasing evidence have shown inflammation may be a significant contributor to observed depressive symptoms. Infliximab is an anti-inflammatory that targets the proinflammatory cytokine Tumour Necrosis Factor Alpha (TNF-α) by inactivating TNF at its active site. The proposed research aim to evaluate the effects on cognitive performance after using an Infliximab therapy in conjunction with conventional mood stabilizers in patients with BD. Both a treatment and a placebo group will be involved in the double-blind study. Depression severity, cognitive performance, cytokine markers, and inflammation levels will all be collected and compared between the two groups to determine significance.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367261
Name
Pan Danny Z
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effect of Anti-Inflammatory Inflixmab on General Cognition in Individuals with Bipolar I/II Depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Inflammatory Agents; Bipolar Depression; Chronic Inflammation; Cognition; Double-Blind; Infliximab; Metabolic Syndrome; Placebo-Controlled; Pro-Inflammatory Cytokines; Tnf-Alpha
Abstract
Bipolar Depression (BD) is a significant contributor to global disability worldwide. Functional impairments such as deficits in cognitive performance after a depressive episode costs the Canadian economy over $6.3 billion annually. Increasing evidence have shown inflammation may be a significant contributor to observed depressive symptoms. Infliximab is an anti-inflammatory that targets the proinflammatory cytokine Tumour Necrosis Factor Alpha (TNF-α) by inactivating TNF at its active site. The proposed research aim to evaluate the effects on cognitive performance after using an Infliximab therapy in conjunction with conventional mood stabilizers in patients with BD. Both a treatment and a placebo group will be involved in the double-blind study. Depression severity, cognitive performance, cytokine markers, and inflammation levels will all be collected and compared between the two groups to determine significance.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pan, Danny Z
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~